Emmanuel Normant

Emmanuel Normant

Company: TG Therapeutics

Job title: VP, Preclinical Sciences

Seminars:

Expert Panel Discussion: Combining Kinase Inhibitor Therapies for Supercharged Targeting 12:30 pm

Discussing multiple points of entry of oncogenic pathways to enhance targeting and therapeutic impact Redefining outcomes with combination therapies across indications, from oncology, dermatology, respiratory & autoimmune diseases Assessing the safety issues with polypharmacy of 1 or more kinases and mitigating off-target effectsRead more

day: Day Two

Uncovering Potential Combinations to Weaponize Kinase Inhibitors Against B Cell Malignancies & Autoimmune Disease 11:30 am

Strategically identifying genes and pathways known to drive the abnormal behaviour of B cells Acquiring and optimizing compounds to develop the best-in-class generation of kinase inhibitors Developing complementary and synergistic drug combinations with TG-1701, umbralisib and ublituximabRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.